Advancing Child Health: Innovative RSV Prevention Strategies in LMICs – Insights from The Lancet Global Health
31 July 2024
The commentary “Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs—reducing global inequity” published in The Lancet Global Health, highlights the significant impact of Respiratory syncytial virus (RSV) on child health, especially in low-income and middle-income countries (LMICs). It emphasises the need for strategies to prevent severe RSV lower respiratory tract infections (LRTI) in infants, given the high disease burden, associated mortality, and limited healthcare access in these regions.
The commentary underscores the urgent need to bridge the gap in healthcare equity. As we strive to advance child health, it is imperative that we ensure the availability of long-acting RSV-monoclonal antibodies to children in LMICs. By prioritising access, we can significantly reduce the burden of severe RSV lower respiratory tract infections and associated mortality.
Access the commentary (full access)
Manuele Piccolis explains:
